Indeed, indoximod enhanced function of tumor-infiltrating effector and helper T cells by inhibiting Trp depletion-associated mTORC1 suppression, thus opposing and bypassing the effects of Trp deprivation that lead to GCN2 activation (97). This evidence concerns the gene EIF2AK4 and neoplasm.